Shares of Fresenius Medical Care AG (ETR:FME - Get Free Report) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of €46.00 ($54.12) and traded as high as €47.95 ($56.41). Fresenius Medical Care shares last traded at €47.49 ($55.87), with a volume of 265,942 shares traded.
Fresenius Medical Care Stock Performance
The firm has a market capitalization of $14.28 billion, a P/E ratio of 21.67, a P/E/G ratio of 0.42 and a beta of 0.86. The company has a debt-to-equity ratio of 82.24, a current ratio of 1.37 and a quick ratio of 0.80. The firm has a 50-day moving average price of €48.37 and a two-hundred day moving average price of €46.02.
About Fresenius Medical Care
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
See Also
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
